RhuDex trial death may be unrelated to drug
This article was originally published in Scrip
Executive Summary
The healthy volunteer who died in MediGene's Phase I study testing rheumatoid arthritis drug candidate RhuDex had impairment of cardiac function that had developed over many years, the German biotech company said after an autopsy was conducted, which could mean that RhuDex was not the cause of death.